AKT1 and non-small cell lung carcinoma: For example, targeted therapy against mTOR, a vital substrate of AKT, has been approved for the treatment of breast, renal, and pancreatic cancers but not lung cancer, and the suboptimal responsiveness in tested NSCLC patients remains to be an unresolved issue34.